• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Quality of Life Improvements in Patients With Chronic Myeloid Leukemia After Stopping Long-Term Therapy: Who Can Benefit the Most?停止长期治疗后慢性髓性白血病患者的生活质量改善：谁能获益最大？
J Natl Cancer Inst. 2022 Jan 11;114(1):9-11. doi: 10.1093/jnci/djab185.
2
Glucose availability in hypoxia regulates the selection of chronic myeloid leukemia progenitor subsets with different resistance to imatinib-mesylate.低氧状态下葡萄糖的可利用性调节慢性髓性白血病祖细胞亚群对甲磺酸伊马替尼耐药性的选择。
Haematologica. 2011 Feb;96(2):204-12. doi: 10.3324/haematol.2010.029082. Epub 2010 Nov 11.
3
Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment.甲磺酸伊马替尼治疗后完全细胞遗传学缓解的慢性髓性白血病患者中恶性造血祖细胞的持续存在。
Blood. 2003 Jun 15;101(12):4701-7. doi: 10.1182/blood-2002-09-2780. Epub 2003 Feb 6.
4
Discontinuation of Imatinib in a Child With Chronic Myeloid Leukemia.一名慢性髓性白血病患儿停用伊马替尼
J Pediatr Hematol Oncol. 2020 Jan;42(1):e64-e65. doi: 10.1097/MPH.0000000000001624.
5
Imatinib mesylate in chronic myeloid leukemia: frontline treatment and long-term outcomes.甲磺酸伊马替尼用于慢性髓性白血病：一线治疗及长期疗效
Expert Rev Anticancer Ther. 2016;16(3):273-8. doi: 10.1586/14737140.2016.1151356.
6
Aberrant DNA methylation at HOXA4 and HOXA5 genes are associated with resistance to imatinib mesylate among chronic myeloid leukemia patients.HOXA4 和 HOXA5 基因的异常 DNA 甲基化与慢性髓性白血病患者对甲磺酸伊马替尼耐药有关。
Cancer Rep (Hoboken). 2018 Aug;1(2):e1111. doi: 10.1002/cnr2.1111. Epub 2018 Jul 27.
7
Molecular studies in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors.接受酪氨酸激酶抑制剂治疗的慢性髓性白血病患者的分子研究。
Semin Hematol. 2001 Jul;38(3 Suppl 8):15-21. doi: 10.1016/s0037-1963(01)90113-1.
8
New strategies in controlling drug resistance in chronic myeloid leukemia.慢性髓性白血病耐药控制的新策略
Am J Health Syst Pharm. 2007 Dec 15;64(24 Suppl 15):S16-21. doi: 10.2146/ajhp070483.
9
Serial monitoring of BCR-ABL transcripts in chronic myelogenous leukemia (CML) treated with imatinib mesylate.对接受甲磺酸伊马替尼治疗的慢性粒细胞白血病（CML）患者的BCR-ABL转录本进行连续监测。
Med Oncol. 2004;21(4):349-58. doi: 10.1385/MO:21:4:349.
10
PD166326, a novel tyrosine kinase inhibitor, has greater antileukemic activity than imatinib mesylate in a murine model of chronic myeloid leukemia.新型酪氨酸激酶抑制剂PD166326在慢性髓性白血病小鼠模型中具有比甲磺酸伊马替尼更强的抗白血病活性。
Blood. 2005 May 15;105(10):3995-4003. doi: 10.1182/blood-2004-09-3534. Epub 2005 Jan 18.

引用本文的文献

1
Health-related quality of life and symptoms of chronic myeloid leukemia patients after discontinuation of tyrosine kinase inhibitors: results from the EURO-SKI Trial.酪氨酸激酶抑制剂停药后慢性髓性白血病患者的健康相关生活质量和症状：来自 EURO-SKI 试验的结果。
Leukemia. 2024 Aug;38(8):1722-1730. doi: 10.1038/s41375-024-02341-4. Epub 2024 Jul 10.
2
Patient- and physician-reported pain after tyrosine kinase inhibitor discontinuation among patients with chronic myeloid leukemia.慢性髓性白血病患者酪氨酸激酶抑制剂停药后患者和医生报告的疼痛。
Haematologica. 2022 Nov 1;107(11):2641-2649. doi: 10.3324/haematol.2021.280377.

本文引用的文献

1
Patient-Reported Functional Outcomes in Patients With Chronic Myeloid Leukemia After Stopping Tyrosine Kinase Inhibitors.慢性髓性白血病患者停止酪氨酸激酶抑制剂治疗后的患者报告功能结局。
J Natl Cancer Inst. 2022 Jan 11;114(1):160-164. doi: 10.1093/jnci/djab184.
2
Quality of life among chronic myeloid leukemia patients in the second-line treatment with nilotinib and influential factors.尼洛替尼二线治疗慢性髓性白血病患者的生活质量及其影响因素。
Qual Life Res. 2022 Mar;31(3):733-743. doi: 10.1007/s11136-021-02952-9. Epub 2021 Jul 14.
3
Molecular response and quality of life in chronic myeloid leukemia patients treated with intermittent TKIs: First interim analysis of OPTkIMA study.间断性 TKI 治疗慢性髓性白血病患者的分子反应和生活质量：OPTkIMA 研究的首次中期分析。
Cancer Med. 2021 Mar;10(5):1726-1737. doi: 10.1002/cam4.3778. Epub 2021 Feb 16.
4
Assessment of Outcomes After Stopping Tyrosine Kinase Inhibitors Among Patients With Chronic Myeloid Leukemia: A Nonrandomized Clinical Trial.酪氨酸激酶抑制剂停药后慢性髓性白血病患者结局评估：一项非随机临床试验。
JAMA Oncol. 2021 Jan 1;7(1):42-50. doi: 10.1001/jamaoncol.2020.5774.
5
Validation and reference values of the EORTC QLQ-CML24 questionnaire to assess health-related quality of life in patients with chronic myeloid leukemia.EORTC QLQ-CML24 问卷评估慢性髓性白血病患者健康相关生活质量的验证和参考值。
Leuk Lymphoma. 2021 Mar;62(3):669-678. doi: 10.1080/10428194.2020.1838509. Epub 2020 Nov 6.
6
European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia.欧洲白血病网络 2020 年治疗慢性髓性白血病的建议。
Leukemia. 2020 Apr;34(4):966-984. doi: 10.1038/s41375-020-0776-2. Epub 2020 Mar 3.
7
Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study.慢性期慢性髓性白血病患者一线使用尼洛替尼后无治疗缓解：ENESTfreedom研究结果
Leukemia. 2017 Jul;31(7):1525-1531. doi: 10.1038/leu.2017.63. Epub 2017 Feb 20.
8
Life Expectancy of Patients With Chronic Myeloid Leukemia Approaches the Life Expectancy of the General Population.慢性髓性白血病患者的预期寿命接近普通人群。
J Clin Oncol. 2016 Aug 20;34(24):2851-7. doi: 10.1200/JCO.2015.66.2866. Epub 2016 Jun 20.
9
Validity and Reliability of the US National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).美国国家癌症研究所患者报告结局版通用不良事件术语标准（PRO-CTCAE）的有效性和可靠性。
JAMA Oncol. 2015 Nov;1(8):1051-9. doi: 10.1001/jamaoncol.2015.2639.
10
Change of health-related profiles after Imatinib cessation in chronic phase chronic myeloid leukemia patients.慢性期慢性髓性白血病患者停用伊马替尼后健康相关状况的变化。
Leuk Lymphoma. 2016 Feb;57(2):341-347. doi: 10.3109/10428194.2015.1049166. Epub 2015 Jun 12.

Quality of Life Improvements in Patients With Chronic Myeloid Leukemia After Stopping Long-Term Therapy: Who Can Benefit the Most?

作者信息

Efficace Fabio, Baccarani Michele

机构信息

Data Center and Health Outcomes Research Unit, Italian Group for Adult Hematologic Diseases (GIMEMA), Rome, Italy.

Department of Hematology, "L. and A. Seràgnoli" University of Bologna and St. Orsola-Malpighi University Hospital, Bologna, Italy.

出版信息

J Natl Cancer Inst. 2022 Jan 11;114(1):9-11. doi: 10.1093/jnci/djab185.

DOI:10.1093/jnci/djab185
PMID:34491364
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8755488/
Abstract
摘要